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Abstract
Background: Intra-operative electrocorticography, based on interictal spikes and spike patterns, is performed to
optimize delineation of the epileptogenic tissue during epilepsy surgery. High frequency oscillations (HFOs, 80–500
Hz) have been identified as more precise biomarkers for epileptogenic tissue. The aim of the trial is to determine
prospectively if ioECoG-tailored surgery using HFOs, instead of interictal spikes, is feasible and will lead to an equal
or better seizure outcome.
Methods\Design: We present a single-blinded multi-center randomized controlled trial “The HFO Trial” including
patients with refractory focal epilepsy of all ages who undergo surgery with intra-operative electrocorticography.
Surgery is tailored by HFOs (arm 1) or interictal spikes (arm 2) in the intra-operative electrocorticography. Primary
outcome is post-operative outcome after 1 year, dichotomized in seizure freedom (Engel 1A and 1B) versus seizure
recurrence (Engel 1C-4). Secondary outcome measures are the volume of resected tissue, neurologic deficits, surgical
duration and complications, cognition and quality of life. The trial has a non-inferiority design to test feasibility and at
least equal performance in terms of surgical outcome. We aim to include 78 patients within 3 years including 1 year
follow-up. Results are expected in 2018.
Discussion: This trial provides a transition from observational research towards clinical interventions using HFOs. We
address methodological difficulties in designing this trial. We expect that the use of HFOs as a biomarker for tailoring
will increase the success rate of epilepsy surgery while reducing resection volume. This may reduce neurological
deficits and yield a better quality of life. Future technical developments, such as validated automatic online HFO
identification, could, together with the attained clinical knowledge, lead to a new objective tailoring approach in
epilepsy surgery.
Trial registration: This trial is registered at the US National Institutes of Health (ClinicalTrials.gov) #NCT02207673
(31 July 2014) and the Central Committee on Research Involving Human Subjects, The Netherlands #NL44257.041.13
(18 March 2014).
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Background
The current success rate of epilepsy surgery in patients
with refractory focal epilepsy lies between 36 and 84 %
after 1 year [1]. Intra-operative electrocorticography
(ioECoG) can be performed during surgery to optimize
delineation of the epileptogenic area by taking into ac-
count interictal spikes or spike patterns. This so called
“tailoring” affects surgical decision-making [2]. Resection
of areas with interictal spikes has been associated with
seizure freedom [3–5], whereas remaining spikes after
resection have been suggested to indicate poor surgical
outcome [2, 3, 6], while other studies contradict this [7–9].
The value of tailoring by interictal spikes can be questioned
as they represent the irritative zone rather than the seizure
onset zone [6], spikes can spread into non-epileptic sur-
rounding areas [6], and can also arise from surgical ma-
nipulation [10]. This leaves tailoring based on spikes in the
ioECoG under international debate. Incomplete resection
of so called “ictiform spike patterns”, consisting of
recruiting patterns, repetitive bursting patterns or con-
tinuous rhythmic spiking, has been reported to predict
poor outcome [11].
High frequency oscillations (HFOs, 80–500 Hz) are pro-
posed as a new and more precise biomarker for epilepto-
genic tissue than spikes [12–20]. HFOs are an indicator of
the seizure onset zone [15]. Removal of tissue with HFOs,
especially fast ripples (FR, 250–500 Hz), is linked to good
surgical outcome [16, 18, 21, 22]. The area showing HFOs
usually overlaps with, but is smaller than the irritative zone
showing spikes [15]. HFOs mirror epileptic disease activity
as they are prominently found in focal cortical dysplasia
(FCD), with increased numbers in the more epileptogenic
FCD type 2 compared to type 1 [17], and they increase
when anti-epileptic drugs are tapered [23]. HFOs can be
recorded during surgery, after anesthetics are reduced [24].
Two decades after their first discovery there is a rising
demand to know whether HFOs can be used in clinical
practice and decision-making [14, 25, 26]. Tailoring based
on HFOs in the ioECoG could improve the chance of seiz-
ure freedom. Other beneficial aspects could be a smaller
resected area, with less chance of neurological deficits,
which – together with an equal or increased seizure
freedom rate – may lead to an overall better quality of
life. Last but not least, the identification of epileptic HFOs
can be automated [12, 27–30] and, therefore, could yield a
future objective approach that is easily implemented.
“The HFO Trial” is a randomized controlled trial (RCT)
designed to investigate the feasibility and safety of using
HFOs during intra-operative tailoring of epilepsy surgery.
The primary objective of this RCT is to validate if tailoring
based on HFOs versus interictal spikes in the ioECoG
during surgery will lead to the same post-surgical seizure
outcome 1 year after surgery (non-inferiority design).
Secondary objectives are comparison of the volume of
resected tissue, the duration of the surgery, the occurrence
of complications and neurologic deficits, and changes in
cognitive functioning and quality of life. RCTs in the field
of epilepsy surgery are not trivial undertakings [31, 32].
We report the details of our study design, and share our
considerations for the trial set-up.
Methods
Trial design
“The HFO Trial” is a single-blinded randomized controlled
Dutch multi-center clinical trial. This trial is based on a
non-inferiority design with an allocation ratio of 1:1. We
chose a non-inferiority design, as we considered the pri-
mary objective of the study, to demonstrate that the intra-
operative prospective use of HFOs to tailor surgery is
feasible and will not lead to worse outcome than the widely
applied method based on spikes. Secondary objectives of
this study are to investigate whether the HFO-based, com-
pared to spike-based, tailoring will lead to differences in
the volume of resected tissue, neurologic deficits, surgical
duration and complications, cognition and quality of life.
Participants
Participants are candidates for epilepsy surgery who are
referred to the Dutch Collaborative Epilepsy Surgery Pro-
gram (DCESP) and are selected to undergo epilepsy sur-
gery with ioECoG-based tailoring. Members of the DCESP
come from the two Dutch epilepsy centers and three
Dutch university medical centers performing epilepsy sur-
gery. The two participating surgical centers in this trial
are: 1) the UMC Utrecht, specialized in pediatric epilepsy
surgery with 75 % of the patients being < 18 years of age
at surgery, and 2) the VUmc Amsterdam, that operates on
adult patients only (≥18 years). Patients and parents or
care givers will be asked to participate if they comply with
the following eligibility criteria:
1) Refractory focal epilepsy, defined as at least 2
seizures in the past 24 months, in spite the use of 2
or more different anti-epileptic drugs (AEDs).
2) Epilepsy surgery planned with ioECoG to tailor the
resection. Note that in the participating centers, this
automatically excludes standard right-sided temporal
resections, disconnections and hemispherectomies in
which no ioECoG is performed.
3) Command of the Dutch language by the patient or
parents\legal representatives and capability of
completing the Dutch questionnaires.
4) Able to give informed consent.
Exclusion criteria are:
1) Previous chronic ECoG (grid) monitoring preceding
epilepsy surgery. This is a biased population, because
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results of the extensive pre-surgical work-up and
the results of the monitoring period determine the
outline of the resection. This includes precise
knowledge of the seizure onset zone, the inter-ictal
spikes and HFO areas.
2) Patients with an occipital focus undergoing ioECoG.
Physiological FRs have been described to occur in the
occipital lobe [33]. We deemed it unsafe to perform
HFO-guided resections in these patients, as it is still
difficult to discriminate between pathological and
physiological HFOs.
Interventions
Participating patients who will undergo ioECoG-tailored
surgery will be randomized into an HFO-guided (arm 1)
or standard epileptiform spikes-guided (arm 2) resection.
The ioECoG is routinely recorded at a sampling fre-
quency of 2048 Hz using clinical electroencephalogram
(EEG) software. A dedicated HFO team, including two
experienced HFO observers, will perform the analysis dur-
ing surgery when the patient has been allocated to the
HFO arm. The HFO reviewers need to achieve consensus
about the HFOs and distinguish them from artifacts. This
team will, together with the clinical neurophysiologist in
charge, advise the neurosurgeon on the extent of the tis-
sue to be resected. HFO analysis is performed visually and
off-line using Stellate Harmonie Reviewer (v7.0, Montreal,
QC, Canada), as this is currently the only clinical EEG
software that provides HFO visualization and marking. A
split screen modus will be used to simultaneously visualize
ripples (settings: finite impulse response (FIR) filter > 80
Hz, gain 5 μV/mm) and fast ripples (settings: FIR filter >
250 Hz, gain 1 μV/mm) at an elongated time interval of
0.4 s/page, according to the settings described in other
studies [15, 18, 21, 22]. Based on pilot data, we expect that
the visual analysis of HFOs will require 50 % more time
compared to the visual analysis of epileptogenic spikes,
which usually takes 3 to 5 minutes per recording. This is
an intention-to-treat study. HFOs in eloquent regions will
not be resected, similar to standard tailoring practice
based on spikes. In absence of HFOs, ictiform spike pat-
terns (for definition see introduction) [11] will always be
resected, irrespective of treatment allocation. If no HFOs
or ictiform spikes are found a planned resection is per-
formed according to size and location of epileptogenic
structural lesion(s), similar to standard clinical practice
when no spikes could be identified.
Outcomes
Primary outcome parameter is the post-surgical seizure
outcome after 1 year based on the Engel classification [34].
Seizure outcome will be dichotomized in seizure freedom
(Engel 1A and 1B) versus seizure recurrence (Engel 1C-4).
We decided to include possible auras (Engel 1B) in the
seizure-free group, because it can be difficult to distinguish
true auras from aura-like non-epileptic sensations. Post-
surgical outcomes at 6 to 8 weeks, 6 and 12 months will be
determined by means of a follow-up questionnaire com-
pleted by the patient or legal representatives. So called
“running down” seizures, seizures occurring only during
the first 2 weeks after surgery are not considered as seizure
recurrence.
Secondary outcome parameters are:
1. Volume of resected tissue (in cm3): the volume of
resected tissue is determined by voxel-based volumetrics
of the routine pre-surgical and post-surgical 3D
whole head T1 magnetic resonance imaging (MRI)
scan.
2. Neurological deficits: neurological deficits are
assessed by neurological examination and translated
into the National Institutes of Health Stroke Scale
(NIHSS) before surgery and before hospital discharge
after surgery. The cumulated NIHSS score ranges
between 0 and 42; a difference of 1 point on the
NIHSS scale between the 2 tests is considered
clinically relevant. In that case the NIHSS will be
repeated at follow-up moments. Additionally,
neurological deficits will be classified as “pre-existing”
(either improved or aggravated) or as “new” (either
anticipated or unexpected).
3. Duration of surgery: post-hoc analysis of duration of
surgery (start-stop time neurosurgeon, in minutes)
and ioECoG recording time (in minutes).
4. Surgical complications: accounts are kept of the
number of (post-) operative complications, such as
bleeding, infection, unexpected or aggravated
neurological deficits. These events will also be
reported as (serious) adverse events ((S)AE).
5. Cognition: comparison of results from pre-operative
and 12-month post-operative neuropsychological
evaluation. This routine neuropsychological evaluation
includes testing of IQ, working memory and processing
speed. All tests performed are chosen according to the
age of the patient, but report on the same domains. Per
domain individual patients’ results will be dichotomized
into negative, no, or positive change compared to
pre-surgical baseline.
6. Quality of life (QoL): QoL will be determined pre-
operatively, and post-operatively after 6 to 8 weeks,
and 6 and 12 months using a visual analog scale
(VAS) on overall self-perceived quality of life, or by
the parents in case of children < 12 years of age.
Data collection, management and storage is done in open
source clinical trial software OpenClinica (OpenClinica,
LLC, Waltham, MA, USA; www.openclinica.com), man-
aged by the IT division of the Neurology and Neurosurgery
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Department of the UMC Utrecht. Figure 1 shows the time-
line of the study procedures.
Sample size
The sample size calculation is based on a success rate of
surgery (defined as Engel 1A or 1B at 1 year) in the con-
trol group (tailoring based on spikes) of 65 %, and the
expected success in the experimental group (HFOs) of
80 %. The resulting margin is 15 %. Using a 1-sided 95 %
confidence interval and a non-inferiority limit of 10 %, to
acquire an 80 % power we need 39 patients per group.
This results in a total of 78 patients. We anticipate that
80 % of the eligible patients will participate in the study.
We expect the potential loss-to-follow-up after the ini-
tial intervention to be low. Routine clinical visits to the
neurosurgeon and neurologist are scheduled after surgery
at 6 to 8 weeks, 6 months and 12 months. Our FU ques-
tionnaires coincide with these visits. Inclusions will proceed
until the target sample size is achieved to address loss to
follow-up. Loss to follow-up can be expected from; 1)
withdrawal by the subject from the study during follow-up
before the first preliminary outcome determination at 6–8
weeks, and 2) withdrawal from the study during the
surgery by the surgeon or dedicated team due to urgent
medical or technical issues.
Subjects are replaced if they withdraw from the study
during follow-up before the first preliminary outcome
determination at 6–8 weeks. Subjects who are withdrawn
from the study during the surgery by the surgeon or dedi-
cated team due to urgent medical or technical issues are
also replaced.
Interim analysis
Safety and efficacy analysis will be performed by the stat-
istician of the independent Data Monitoring Committee
(DMC) after the first 20 and 40 included patients. This
analysis will be based on the available, preliminary, post-
surgical outcomes and also includes the number of sur-
gical complications and (serious) adverse events ((S)AE).
The DMC can advise on premature termination of the
study in case of harmful effects, or superiority, in one of
the treatment arms or in case of non-feasibility issues.
Randomization
Eligible epilepsy surgery patients and/or parents or care-
givers will be informed about this study by the researcher
Fig. 1 Timeline of the study procedures. On the day prior to surgery, the patient signs the informed consent form and subsequently the baseline
questionnaire and neurological examination (by means of National Institutes of Health Stroke Scale (NIHSS)) are completed and the patient is
enrolled in the study by randomization. Note that the follow-up questionnaire collects information about (preliminary) outcome, anti-epileptic drug
use, quality of life and occurrence of (serious) adverse events. Additional information is collected from routine clinical tests that are performed during
the pre-surgical and post-surgical period
Fig. 2 Logotype “The HFO Trial”
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in person, minimally 2 weeks in advance of the surgery.
Informed consent is asked on the day prior to the day of
surgery. After written consent, the patient will be random-
ized into the treatment allocation (ALEA version-release
2.2). Stratification for participating site and epilepsy type
(extra-temporal versus temporal lobe epilepsy) is per-
formed using block randomization of 2, 4 and 6 patients.
The stratification for participation site includes an indirect
stratification for age, as in the VUmc only adults and in
the University Medical Center Utrecht (UMCU) predom-
inantly children are operated on.
Blinding
Blinding of the treating physicians and neurosurgeons
for treatment allocation is not feasible because of the
character of the intervention. Therefore, this is a single-
blinded trial as patients will be blinded for the treatment
allocation to avoid bias of the follow-up results. To guar-
anty the blinding of the patient, the outpatient physicians,
neurologist and psychologist involved in the follow-up
procedures are blinded for the ioECoG report during the
entire period of follow-up. After study completion or
termination patients who wish so will be de-blinded.
Statistical methods
The primary “intention-to-treat” analyses at study comple-
tion are based on the difference between the treatment
arms with respect to surgical outcome after 12 months.
The primary outcome is a categorical outcome, seizure
freedom versus seizure recurrence. Risk ratios (RR) and
risk difference with 95 % confidence interval will be
calculated (X2- test, 1-sided). Secondary outcomes are
the amount of tissue resected, neurological deficits, dur-
ation of surgery, complications, cognition and quality of
life. For the secondary outcome parameters consisting of
continuous variables, a T-test with 95 % confidence inter-
val is calculated and tested (1-sided). For the secondary
outcome parameters consisting of categorical variables,
the RR and risk difference with a 95 % confidence interval
are calculated and tested using a Chi-square test (1-sided).
Logistic regression analysis will be performed: 1) to adjust
for the stratification factors, by including site and epilepsy
type as variables in analysis, and 2) to investigate if there
are relations between seizure outcome and subject vari-
ables, such as age, gender, and pathology, or with experi-
mental variables, such as the operating surgeon and the
amount of anesthesia received. Note that we are not going
to use a mixed model to adjust for site, as we consider
two sites too small a sample to be representative for other
sites. Regression analysis is also performed between
seizure outcome and the secondary outcome parameters.
In the logistic regression analysis we will, after screen-
ing of the number of missing data, perform multiple im-
putation. For the primary and secondary endpoint no
imputation will be performed. Statistical analysis will be
performed in SPSS version 21 (SPSS Inc., Chicago, IL,
USA) or higher and/or R version 3.1 or higher.
The number of eligible patients withholding consent
will be registered, and demographic information will be
collected anonymously for post-hoc explorative analysis
to understand potential bias in study outcomes.
Safety aspects
Adverse events (AEs) are defined as any undesirable ex-
perience occurring to a subject during the study, whether
or not considered related to the experimental treatment.
A SAE is defined as any untoward medical occurrence or
effect that results in death, is life-threatening, requires
(prolonged) hospitalization, results in persistent or signifi-
cant disability or incapacity, or is a new event of the trial
that is likely to affect the safety of the subjects. We will
not report the majority of direct postsurgical complaints,
such as nausea, headache, abdominal pains or pain related
to the surgical scar during the hospitalization period, as
AEs, as those result directly from brain surgery and will
resolve before discharge. Similarly, direct post-operative
functional deficits, due to surgically induced cerebral
edema, will often resolve prior to discharge; these will
not be reported as (S)AE. SAEs will be closely monitored
by the researchers within the timeframe of hospital ad-
mission (normal range ≤ 10 days after surgery). The
neurological deficits will be assessed with the NIHSS
questionnaire (see also neurological deficits). During the 1
year follow-up period all reported AEs and SAEs, inde-
pendent of the site, will be registered by the researchers
and reported to the DMC. SAEs are reported to the
Medical Ethics Committee.
Ethical considerations
Informed consent will be obtained from all participants
and/or their legal representative(s), in writing, before in-
clusion in the trial. “The HFO Trial” protocol has been
approved by the Medical Ethics Committee of the UMC
Utrecht (MEC-13-389). “The HFO Trial” is registered at
the US National Institutes of Health (ClinicalTrials.gov)
#NCT02207673 and the Central Committee on Re-
search Involving Human Subjects, The Netherlands
#NL44257.041.13.
Discussion
We announce, by reporting our study design, the start of
the “The HFO Trial,” a multi-center RCT in epilepsy sur-
gery. This is the first clinical trial investigating tailoring
based on biomarkers in the ioECoG, i.e. HFOs versus
interictal spikes, with respect to post-surgical seizure
outcome.
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Trials in epilepsy surgery
RCTs are considered the “gold standard” for evaluating
therapeutic interventions, but surgical RCTs are challen-
ging and only few have successfully been completed in
the field of epilepsy surgery. So far 13 RCTs were per-
formed in the period 1992–2012, and 5 of them, all in
temporal lobe resections, investigated a new surgical strat-
egy or compared AED prescription versus (early) surgery
[31, 35]. Currently, five ongoing RCTs in the field of epi-
lepsy surgery are registered on the international trial regis-
ter “clinicaltrials.gov.” Two of these RCTs investigate a
new surgical strategy, including the trial reported here.
Considerations
An important consideration in RCTs in epilepsy surgery
is feasibility, which is influenced by the (in)ability of
recruiting enough eligible patients with sufficient speed.
The difficulty to standardize diagnostic testing, medical
treatment and surgical interventions across multiple cen-
ters is of great influence [31, 32, 35]. In the Netherlands,
all epilepsy surgery is performed in three medical centers
and is embedded in the Dutch Collaborative Epilepsy
Surgery Program (DCESP) [36]. Cases are discussed within
this national team of (pediatric) neurologists, clinical
neurophysiologist, (pediatric) neuropsychologists, nurse
practitioners, physician assistants, radiologists and sur-
geons. This unique collaboration secures more or less
standardized protocols and consistent indications for
eligibility and treatment. The small distance (<50 km)
between the 2 centers in Amsterdam and Utrecht gives
us the opportunity to have 1 dedicated HFO team to
execute the trial in both centers, including the HFO
analysis during surgery.
We chose post-surgical outcome as primary outcome
parameter, as the ultimate goal of epilepsy surgery is to
achieve seizure freedom. This is the most relevant clin-
ical parameter as the number of seizures and the side ef-
fects of AED use are the main determinants of QoL in
epilepsy patients [1]. We chose to differentiate between
seizure freedom ± auras (good outcome) and seizure re-
currence (poor outcome) although in the literature, good
outcome is often defined as Engel 1 and 2 [15, 16]. We
deliberately applied this stricter definition, because we
aim to find and remove all epileptogenic tissue based on
HFOs and thus aim for seizure freedom as completely as
possible. We included auras in the good outcome group,
because distinction of the presence or absence of aura
sensations in the first year after surgery, while still using
AEDs, may be subjective. We will add post-hoc analyses
using other dichotomies of the outcome score (for ex-
ample, Engel 1A versus all others). These analyses might
help to design future prospective studies. Recent studies
have suggested that early AED withdrawal does not affect
long-term seizure outcome or cure. It might unmask
incomplete surgical success sooner [37]. Definite proof
of complete removal of potentially epileptogenic tissue
requires enduring seizure freedom over many years with-
out the use of AEDs. We will collect information about
AED use during follow-up for post-hoc analysis.
Previous epilepsy surgical RCTs included patients with
intractable epilepsy with a minimal age of 12 years [31].
Including children in clinical trials is inextricably con-
nected to ethical concerns [26]. A shift in epilepsy surgery
towards the pediatric population has, however, been set in
motion over the last years and the proportion of young
children who undergo epilepsy surgery is increasing [36].
Children are considered for early epilepsy surgery now-
adays because successful resection of epileptic foci may
lead to seizure freedom and medication freedom, and may
improve social, psychological and cognitive development
[38, 39]. We chose to include children, irrespective of age,
because the research question about seizure outcome and
the expected smaller resection that might reduce neuro-
logical and cognitive deficits are most relevant in this
population. Limiting inclusion solely to adults would not
only provide a lower number of eligible patients for par-
ticipation, but would exclude the patient population who
might benefit most.
We chose for a non-inferiority design to support feasi-
bility of the trial, although literature findings suggest
that HFOs are the superior biomarker for epileptogenic
tissue rather than spikes [12, 13, 15, 16, 18–21, 29, 28].
The limiting factor of a superiority design is the large
sample size needed, which would require participation
of more than two centers. Currently, the few HFO ex-
perts and the fact that the surgeries and HFO analyses
are time consuming limit the number of participating
centers and patients. We consider the most important
aspect of the study to assess the feasibility of using
HFOs for tailoring. We think it is also important, at the
same time, that automated ways of analysis are developed
and implemented [27, 30], since these are indispensable
for clinical application in other centers. Together with this
trial this could set the stage for a larger, international RCT
aimed at proving actual superiority of HFOs.
Our power calculation is based on estimated success
rates deduced from retrospective studies up until 2013.
These studies consisted of different patient populations.
The current success rate of epilepsy surgery based on the
old treatment, tailoring based on spikes, lies around 65 %;
in resections for temporal lobe epilepsy (TLE) 60–90 % of
patients achieve seizure freedom while in extra-temporal
epilepsy it is around 40–65 % [40, 41]. We expected an in-
crease in success percentage of 15 % leading to 80 % for
HFOs based on retrospective studies in which part of the
patients, with surgery based on spikes, had incomplete
removal of HFO tissue and poor outcome [18], while
incomplete removal of spikes does not predict seizure
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recurrence [15, 16]. We are aware that we chose a rela-
tively large effect size. An overestimation of the success
rate for the outcome in the HFO arm could lead to
non-significant finding due to too a small population.
Before we started with this RCT, we retrospectively stud-
ied our own ioECoG data in order to validate previous
findings [22]. We found good outcome (Engel 1A and 1B
after 1 year) in 70 % of patients and tailoring based on
FRs could have improved outcome in 15 % of these
patients [22].
This study also gave rise to the question whether or
not we need to discriminate between epileptic and physio-
logical HFOs, as we found some FRs, although far away
from the area of resection and in functionally eloquent
areas such as the sensorimotor and Broca’s areas, after
resection in two patients who were seizure-free and
medication-free. This means that we have to be careful
when assessing HFOs in eloquent areas. In our retrospect-
ive data analysis we found that residual FRs were strongly
related to epileptic tissue and poor outcome, while for
ripples we found no association [22].
Tailoring based on spikes in the ioECoG is not an
evidence-based method, as no RCT has compared tailoring
to resection without ioECoG, but we relate to it as the
“gold standard” [6]. The same restrictions for tailoring are
valid for HFOs as for spikes. The ioECoG might either
confirm the surgical plan or change the surgical plan, but
reduction or extension of the planned resection might be
limited by eloquent cortex or anatomy. Events, spikes or
HFOs, occurring remote from the resection site are usually
not considered indicative for removal. Upfront it may be
hard to tell if tailoring will really influence the surgical
plan, even though in our population we aim to perform
ioECoG only with a valid indication. We will, prospect-
ively, collect data on the influence of events on the ac-
tual clinical decision and perform a post-hoc analysis to
clarify in which patients tailoring actually changed the
surgical plan.
The visual analysis of HFOs requires experienced ob-
servers, and additional analysis time due to the offline
analysis and expanded time settings for ECoG display. We
estimate this additional analysis time is 5 to 10 minutes
per ioECoG recording, compared to spike analysis. A
disadvantage of using spikes is that they have a lower
inter-observer agreement compared to HFOs [42]. An
associated risk of the use of HFOs is undersampling
and underdetection of HFOs compared to spikes, as HFOs
are a more local phenomena than spikes [15], and the
negative effect of anesthetics on the number of HFOs
[24]. These concerns are preempted similar as for the
procedures during tailoring based on spikes; multiple
recordings are made before and after resection, where
the sampling strategy is based on the results in previous
recordings to guaranty optimal sampling. All recordings
are made while tapering the propofol until a continuous
EEG pattern can be seen.
Expected benefit
We believe that an RCT is the proper way to prospectively
test the beneficial properties of HFOs as a new biomarker
for delineation of epileptogenic tissue and eventually im-
prove the success rate of epilepsy surgery. Retrospective re-
search suggests that HFOs are more specific and precise
biomarkers for the epileptogenic zone than spikes. Complete
resection of the epileptic focus may lead to seizure freedom
and medication freedom, and may improve social, psy-
chological and cognitive development, especially in chil-
dren. Potential benefits from a smaller or more precise
resection would be reduced neurological deficits and, com-
bined with equal or better seizure outcome, should im-
proved quality of life. The identification of HFOs can be
standardized and automated and thereby potentiate an ob-
jective tailoring approach for international implementation.
Trial status
The first patient was enrolled in “The HFO Trial” on 6
November 2014 in the UMC Utrecht. Figure 2 shows
the logotype of the “The HFO Trial”. At the moment of
acceptance of this manuscript, August 2015, in total 10
patients have been included. Enrollment at the second
site, VUmc Amsterdam, will start in autumn 2015. Results
are expected in 2018.
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